|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||151.00 - 151.71|
|52 Week Range||123.53 - 156.54|
|PE Ratio (TTM)||62.67|
|Expense Ratio (net)||0.10%|
Eli Lilly’s (LLY) human pharmaceutical business reported revenues of $5.0 billion in 2Q17, an 11.0% rise compared to $4.5 billion in 2Q16.
On September 20, 2016, Regeneron (REGN) entered into a partnership with Teva Pharmaceutical (TEVA) for the development and commercialization of Fasinumab in the US.
Sage Therapeutics (SAGE) is a clinical-research-based biopharmaceutical company focused on developing drugs for life-threatening central nervous system disorders.
In August 2017, Jazz Pharmaceuticals (JAZZ) and ImmunoGen (IMGN) entered into a strategic collaboration and option agreement.
Bristol Myers Squibb’s (BMY) Opdivo reported revenues of $1.2 billion during 2Q17, a rise of 42.0% compared to $840.0 million in 2Q16.
Becton Dickinson (BDX) has seen tremendous growth in recent years, driven by some of its major acquisitions and key product launches.
Johnson & Johnson’s (JNJ) pharmaceutical segment comprises the cardiovascular, metabolics, immunology, infectious disease, neuroscience, oncology, and pulmonary hypertension franchises. The cardiovascular ...
Allergan (AGN) is a leading pharmaceuticals company involved with pharmaceuticals, over-the-counter products, eye care, and aesthetics products.
In its Tones-2 study, JAZZ studied the efficacy and safety of JZP-110 to control excessive sleepiness in narcolepsy patients over a period of 12 weeks.
Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts ...
In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues ...
As we discussed earlier in this series, Pfizer (PFE) reported a 2% decline in revenues to $12.89 billion in 2Q17, compared to revenues of $13.15 billion in 2Q16.
ABBVie anticipates upadacitinib to be commercialized by 2019. If approved, AbbVie’s upadacitinib will directly compete with Pfizer’s (PFE) Xeljanz.
Bristol-Myers Squibb (BMY) met Wall Street analysts’ consensus estimate for earnings per share (or EPS) in 2Q17, reporting EPS of $0.74.
Analysts expect a 0.5% fall in Pfizer’s (PFE) 2Q17 revenues to $13.08 billion, following a decline in revenues from blockbuster drugs including Celebrex, Zyvox, and Lyrica.
In 2016, Pfizer’s (PFE) Medrol reported revenues of ~$450 million, which represented a ~12% rise on a YoY (year-over-year) basis.
The S&P 500 (SPY) index reached another peak last week, driven by solid earnings by major US corporations. The index was at 2,472.54, with a gain of 0.54%, taking the…